Pain Therapy Drugs Market – New Report from Espicom

Welcome back to the Pharmaceutical News. Hope everyone had a lovely break over the Christmas period and are now looking forward to a prosperous 2012!

Just as a heads-up we have a new report from Espicom entitled Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development for a snippet from the sales page, please click on the link below to

>>> Pain Therapy Drugs Market <<<

Here are some of the questions that this report will answer;

•     To what extent will generic competition affect Lilly’s leading pain drug Cymbalta from 2013 onwards?

•     What legal challenges must Pfizer overcome if Lyrica is to achieve its forecast sales of US$4.2 billion in 2017?

•     What clinical benefits does GW Pharmaceuticals’ Sativex offer in the MS market and does the product have new indication opportunities?

•     Grünenthal’s Palexia/Nucynta (also marketed by Johnson & Johnson in the US) is widely tipped for rapid growth due to its dual action and better tolerability profile over its opioid competitors. But will these benefits be enough to challenge the lower price of generically available competitors in the future?

•     How did Pfizer improve its market share in 2011 in the pain sector?

•     What techniques are being employed to overcome opioid abuse?

•     Who is developing products that target cancer-related pain?

•     What do the market leaders have in their Phase I/II pipelines?

For more info check it out first here Pain Therapy Drugs Market

Tagged with: Cymbalta • Duloxetine • episcom report pain • Espicom • Johnson & Johnson • Medicine • Pain management • Pfizer • pharmaceutical news report • Pregabalin

Filed under: Pharmaceutical News

Like this post? Subscribe to my RSS feed and get loads more!